Source:http://linkedlifedata.com/resource/pubmed/id/19762222
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
2009-10-5
|
| pubmed:abstractText |
Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART) reduces asthma exacerbations and symptoms versus fixed-dose regimens plus short-acting beta(2)-agonists (SABA) in double-blind trials. Information is lacking regarding its effectiveness versus conventional best practice (CBP). This pooled analysis of six 6-month, randomized, open-label studies examined asthma control and exacerbation risk in asthmatics (aged> or =12 years). Patients (N=7855) symptomatic on inhaled corticosteroids (ICS) or stable/symptomatic on ICS/long-acting beta(2)-agonists (LABA) received budesonide/formoterol maintenance and reliever therapy (160/4.5microg bid and as needed) or CBP (ICS or ICS/LABA+/-other agents at an approved dose plus as-needed SABA). Overall asthma control was assessed comparing the incidence of exacerbations and levels of asthma control using the asthma control questionnaire (ACQ). Budesonide/formoterol maintenance and reliever therapy did not significantly reduce time to first severe exacerbation (primary variable) versus CBP (P=0.062). However, patients in this group experienced 15% fewer exacerbations (0.20 versus 0.24/patient/year; P=0.021) and used 27% less ICS (P<0.0001). Odds of remaining well controlled (ACQ< or =0.75) over 6 months were higher with budesonide/formoterol maintenance and reliever therapy versus CBP (45% versus 41%, odds ratio [OR] 1.29; P<0.01) while risk of remaining uncontrolled decreased (25% versus 29%, OR 0.81; P<0.01). Budesonide/formoterol maintenance and reliever therapy improves key aspects of asthma control versus physicians' choice of CBP.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Bronchodilator Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Budesonide,
http://linkedlifedata.com/resource/pubmed/chemical/Ethanolamines,
http://linkedlifedata.com/resource/pubmed/chemical/formoterol
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
1532-3064
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
103
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1623-32
|
| pubmed:meshHeading |
pubmed-meshheading:19762222-Adolescent,
pubmed-meshheading:19762222-Adrenergic beta-Agonists,
pubmed-meshheading:19762222-Adult,
pubmed-meshheading:19762222-Aged,
pubmed-meshheading:19762222-Aged, 80 and over,
pubmed-meshheading:19762222-Asthma,
pubmed-meshheading:19762222-Bronchodilator Agents,
pubmed-meshheading:19762222-Budesonide,
pubmed-meshheading:19762222-Child,
pubmed-meshheading:19762222-Double-Blind Method,
pubmed-meshheading:19762222-Drug Therapy, Combination,
pubmed-meshheading:19762222-Ethanolamines,
pubmed-meshheading:19762222-Female,
pubmed-meshheading:19762222-Humans,
pubmed-meshheading:19762222-Male,
pubmed-meshheading:19762222-Middle Aged,
pubmed-meshheading:19762222-Practice Guidelines as Topic,
pubmed-meshheading:19762222-Randomized Controlled Trials as Topic,
pubmed-meshheading:19762222-Severity of Illness Index,
pubmed-meshheading:19762222-Treatment Outcome,
pubmed-meshheading:19762222-Young Adult
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Budesonide/formoterol maintenance and reliever therapy versus conventional best practice.
|
| pubmed:affiliation |
University Hospital of Montpellier and INSERM U, Hôpital Arnaud de Villeneuve, France. pascal.demoly@inserm.fr
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|